Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a post-merger biomedical company focused on cardiovascular therapies, including its BackBeat cardiac neuromodulation system targeting hypertension. The company became publicly listed in early 2023 following its business combination with Health Assurance Acquisition Corp, a healthcare-focused SPAC that completed its IPO in 2020 and was sponsored by Health Assurance Acquisition Corp Management LLC, a vehicle associated with Evolent Health co-founder Frank Williams. On April 29, 2026, Orchestra BioMed filed a DEF 14A proxy statement with the SEC ahead of its annual shareholder meeting, reflecting its ongoing obligations as a reporting public company in the medical devices and cardiovascular sector. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on OBIO and hundreds of other SPAC-originated companies.